Zacks: Brokerages Anticipate BIONDVAX PHARMA/S (BVXV) to Announce -$0.01 EPS

Brokerages predict that BIONDVAX PHARMA/S (NASDAQ:BVXV) will post earnings of ($0.01) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for BIONDVAX PHARMA/S’s earnings. BIONDVAX PHARMA/S posted earnings of $0.20 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 105%. The business is expected to issue its next quarterly earnings report on Tuesday, November 27th.

According to Zacks, analysts expect that BIONDVAX PHARMA/S will report full-year earnings of ($0.05) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.04) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for BIONDVAX PHARMA/S.

BIONDVAX PHARMA/S (NASDAQ:BVXV) last released its quarterly earnings data on Wednesday, August 22nd. The company reported ($1.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($1.11).

Separately, ValuEngine cut shares of BIONDVAX PHARMA/S from a “hold” rating to a “sell” rating in a research report on Thursday, August 23rd.

Shares of BVXV traded up $0.06 during trading hours on Friday, reaching $5.41. The stock had a trading volume of 2,910 shares, compared to its average volume of 5,027. The company has a quick ratio of 19.79, a current ratio of 19.79 and a debt-to-equity ratio of 1.24. BIONDVAX PHARMA/S has a 52 week low of $4.60 and a 52 week high of $7.71. The stock has a market cap of $34.83 million, a P/E ratio of -2.73 and a beta of 1.01.


BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.

Featured Article: What impact do institutional investors have on markets?

Get a free copy of the Zacks research report on BIONDVAX PHARMA/S (BVXV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with's FREE daily email newsletter.

Leave a Reply